These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

796 related articles for article (PubMed ID: 24509406)

  • 1. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R; Kerr B; Yeh LT; Suster M; Shen Z; Polvent E; Hingorani V; Quart B; Manhard K; Miner JN; Baumgartner S;
    Rheumatology (Oxford); 2014 Dec; 53(12):2167-74. PubMed ID: 24509406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.
    Shiramoto M; Liu S; Shen Z; Yan X; Yamamoto A; Gillen M; Ito Y; Hall J
    Rheumatology (Oxford); 2018 Sep; 57(9):1602-1610. PubMed ID: 29868853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S; Yeh LT; Shen Z; Kerr B; Manhard K; Quart B
    J Clin Pharmacol; 2018 Sep; 58(9):1164-1170. PubMed ID: 29733441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Kopicko J; Bhakta N; Adler S; Fung M; Storgard C; Baumgartner S; Perez-Ruiz F
    Arthritis Rheumatol; 2017 Sep; 69(9):1903-1913. PubMed ID: 28597604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of Pharmacokinetic Interactions Between Lesinurad, a New Selective Urate Reabsorption Inhibitor, and Commonly Used Drugs for Gout Treatment.
    Shen Z; Tieu K; Wilson D; Bucci G; Gillen M; Lee C; Kerr B
    Clin Pharmacol Drug Dev; 2017 Jul; 6(4):377-387. PubMed ID: 28074640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
    Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study).
    Bardin T; Keenan RT; Khanna PP; Kopicko J; Fung M; Bhakta N; Adler S; Storgard C; Baumgartner S; So A
    Ann Rheum Dis; 2017 May; 76(5):811-820. PubMed ID: 27821644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
    Ernst ME; Fravel MA
    Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY; Chang YT; Lin YC; Lee CH; Loh EW; Wu MY; Chang YS; Tam KW
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urate-lowering therapy for gout: focus on febuxostat.
    Love BL; Barrons R; Veverka A; Snider KM
    Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Huang X; Du H; Gu J; Zhao D; Jiang L; Li X; Zuo X; Liu Y; Li Z; Li X; Zhu P; Li J; Zhang Z; Huang A; Zhang Y; Bao C
    Int J Rheum Dis; 2014 Jul; 17(6):679-86. PubMed ID: 24467549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N; Jones G; Terkeltaub R; Khanna D; Fung M; Baumgartner S; Perez-Ruiz F
    Arthritis Res Ther; 2019 Jan; 21(1):8. PubMed ID: 30616614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled, double-blind study of the non-purine-selective xanthine oxidase inhibitor Febuxostat (TMX-67) in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
    Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
    J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S19-26. PubMed ID: 21654266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.